Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Cabotegravir (Primary) ; Rifabutin
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 26 May 2017 Planned End Date changed from 11 Aug 2017 to 18 Aug 2017.
- 26 May 2017 Planned primary completion date changed from 11 Aug 2017 to 18 Aug 2017.
- 17 May 2017 New trial record